ARQT compared with PVLA: revenue, margins and what each company keeps, and the suppliers and customers both name

ARQTArcutis Biotherapeutics, Inc.

Mkt capRevenueRevenue

PVLAPalvella Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ARQTArcutis Biotherapeutics, Inc.

PVLAPalvella Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARQT

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.3%▼−20.70%×1.68

Q2 FY26±10.2%▼−2.47%×0.25

Q1 FY26±13.1%▲+5.78%×0.44

Q3 FY25±15.7%▲+27.04%×1.72

PVLA

2 of 3at or beyond implied

Reportimpliedrealized× implied

Nov 5 '26±8.2%▼−3.35%×0.41

Aug 4 '26—▲+7.96%—

= impliedARQT realized, solidPVLA realized, hatchedOne scale, both sides: full bar = 28%× = |realized| ÷ impliedspan: ARQT 373d · PVLA 219dSource: market data

May 7 '26

±8.6%

▼−12.99%

×1.51

Mar 31 '26±11.9%▲+12.64%×1.06

ARQTArcutis Biotherapeutics, Inc.

25.55▼−5.38%· post 25.56

Mkt cap$3.2BRevenue$144MQ3 FY26Revenue$376MFY25

PVLAPalvella Therapeutics, Inc.

174.90▲+11.51%· post 174.90

ClosedNov 6 '26

Mkt cap—Revenue—Revenue—

Compare

ClosedNov 6 '26

ARQTArcutis Biotherapeutics, Inc.

PVLAPalvella Therapeutics, Inc.

25.55▼−5.38%post 25.56

Price

174.90▲+11.51%post 174.90

$3.2B

Mkt cap

—

Q3 FY26$144M

Revenue

—

FY25$376M

Revenue

—

ARQT25.55▼−5.38%vsPVLA174.90▲+11.51%ClosedNov 6 '26